Cargando…
In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c)
Nicotinamide-nucleotide adenylyl transferase (Rv2421c) was selected as a potential drug target, because it has been shown, in vitro, to be essential for Mycobacterium tuberculosis growth. It is conserved between mycobacterium species, is up-regulated during dormancy, has a known 3D crystal structure...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562812/ https://www.ncbi.nlm.nih.gov/pubmed/34727137 http://dx.doi.org/10.1371/journal.pone.0259348 |
_version_ | 1784593317832425472 |
---|---|
author | Cloete, Ruben Shahbaaz, Mohd Grobbelaar, Melanie Sampson, Samantha L. Christoffels, Alan |
author_facet | Cloete, Ruben Shahbaaz, Mohd Grobbelaar, Melanie Sampson, Samantha L. Christoffels, Alan |
author_sort | Cloete, Ruben |
collection | PubMed |
description | Nicotinamide-nucleotide adenylyl transferase (Rv2421c) was selected as a potential drug target, because it has been shown, in vitro, to be essential for Mycobacterium tuberculosis growth. It is conserved between mycobacterium species, is up-regulated during dormancy, has a known 3D crystal structure and has no known human homologs. A model of Rv2421c in complex with nicotinic acid adenine dinucleotide and magnesium ion was constructed and subject tovirtual ligand screening against the Prestwick Chemical Library and the ZINC database, which yielded 155 potential hit molecules. Of the 155 compounds identified five were pursued further using an IC50 based 3D-QSAR study. The 3D-QSAR model validated the inhibition properties of the five compounds based on R(2) value of 0.895 and Q(2) value of 0.944 compared to known inhibitors of Rv2421c. Higher binding affinities was observed for the novel ZINC13544129 and two FDA approved compounds (Novobiocin sodium salt, Sulfasalazine). Similarly, the total interaction energy was found to be the highest for Cromolyn disodium system (-418.88 kJ/mol) followed by Novobiocin (-379.19 kJ/mol) and Sulfasalazine with (-330.13 kJ/mol) compared to substrate DND having (-185.52 kJ/mol). Subsequent in vitro testing of the five compounds identified Novobiocin sodium salt with activity against Mycobacterium tuberculosis at 50 μM, 25μM and weakly at 10μM concentrations. Novobiocin salt interacts with a MG ion and active site residues His20, Thr86, Gly107 and Leu164 similar to substrate DND of Mycobacterium tuberculosis Rv2421c. Additional in silico structural analysis of known Novobiocin sodium salt derivatives against Rv2421c suggest Coumermycin as a promising alternative for the treatment of Mycobacterium tuberculosis based on large number of hydrogen bond interactions with Rv2421c similar in comparison to Novobiocin salt and substrate DND. |
format | Online Article Text |
id | pubmed-8562812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-85628122021-11-03 In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c) Cloete, Ruben Shahbaaz, Mohd Grobbelaar, Melanie Sampson, Samantha L. Christoffels, Alan PLoS One Research Article Nicotinamide-nucleotide adenylyl transferase (Rv2421c) was selected as a potential drug target, because it has been shown, in vitro, to be essential for Mycobacterium tuberculosis growth. It is conserved between mycobacterium species, is up-regulated during dormancy, has a known 3D crystal structure and has no known human homologs. A model of Rv2421c in complex with nicotinic acid adenine dinucleotide and magnesium ion was constructed and subject tovirtual ligand screening against the Prestwick Chemical Library and the ZINC database, which yielded 155 potential hit molecules. Of the 155 compounds identified five were pursued further using an IC50 based 3D-QSAR study. The 3D-QSAR model validated the inhibition properties of the five compounds based on R(2) value of 0.895 and Q(2) value of 0.944 compared to known inhibitors of Rv2421c. Higher binding affinities was observed for the novel ZINC13544129 and two FDA approved compounds (Novobiocin sodium salt, Sulfasalazine). Similarly, the total interaction energy was found to be the highest for Cromolyn disodium system (-418.88 kJ/mol) followed by Novobiocin (-379.19 kJ/mol) and Sulfasalazine with (-330.13 kJ/mol) compared to substrate DND having (-185.52 kJ/mol). Subsequent in vitro testing of the five compounds identified Novobiocin sodium salt with activity against Mycobacterium tuberculosis at 50 μM, 25μM and weakly at 10μM concentrations. Novobiocin salt interacts with a MG ion and active site residues His20, Thr86, Gly107 and Leu164 similar to substrate DND of Mycobacterium tuberculosis Rv2421c. Additional in silico structural analysis of known Novobiocin sodium salt derivatives against Rv2421c suggest Coumermycin as a promising alternative for the treatment of Mycobacterium tuberculosis based on large number of hydrogen bond interactions with Rv2421c similar in comparison to Novobiocin salt and substrate DND. Public Library of Science 2021-11-02 /pmc/articles/PMC8562812/ /pubmed/34727137 http://dx.doi.org/10.1371/journal.pone.0259348 Text en © 2021 Cloete et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Cloete, Ruben Shahbaaz, Mohd Grobbelaar, Melanie Sampson, Samantha L. Christoffels, Alan In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c) |
title | In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c) |
title_full | In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c) |
title_fullStr | In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c) |
title_full_unstemmed | In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c) |
title_short | In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c) |
title_sort | in silico repurposing of a novobiocin derivative for activity against latency associated mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (rv2421c) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562812/ https://www.ncbi.nlm.nih.gov/pubmed/34727137 http://dx.doi.org/10.1371/journal.pone.0259348 |
work_keys_str_mv | AT cloeteruben insilicorepurposingofanovobiocinderivativeforactivityagainstlatencyassociatedmycobacteriumtuberculosisdrugtargetnicotinatenucleotideadenylyltransferaserv2421c AT shahbaazmohd insilicorepurposingofanovobiocinderivativeforactivityagainstlatencyassociatedmycobacteriumtuberculosisdrugtargetnicotinatenucleotideadenylyltransferaserv2421c AT grobbelaarmelanie insilicorepurposingofanovobiocinderivativeforactivityagainstlatencyassociatedmycobacteriumtuberculosisdrugtargetnicotinatenucleotideadenylyltransferaserv2421c AT sampsonsamanthal insilicorepurposingofanovobiocinderivativeforactivityagainstlatencyassociatedmycobacteriumtuberculosisdrugtargetnicotinatenucleotideadenylyltransferaserv2421c AT christoffelsalan insilicorepurposingofanovobiocinderivativeforactivityagainstlatencyassociatedmycobacteriumtuberculosisdrugtargetnicotinatenucleotideadenylyltransferaserv2421c |